Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the Prospective Multicenter Observational HepaStar Trial
European Radiology · 2024
DOI: 10.1007/s00330-024-11272-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Radiology, 2024. Verfasst von Federico Collettini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Charité University Medicine Berlin Berlin, Charitéplatz 1, 10117, Berlin, Germany. federico.collettini@charite.de. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Starch. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Magle PharmaCept GmbH.
Abstract (Originalsprache)
Objectives
Despite increasing interest, prospective data on the use of degradable starch microsphere-transarterial chemoembolization (DSM-TACE) in the management of patients with unresectable HCC are still scarce. The objective of the HepaStar study was to collect prospective safety and effectiveness data in a prospective multicenter observational study. Materials and methods Between January 2017 and December 2022, consecutive participants with unresectable or recurrent HCC treated with DSM-TACE as standard of care at 6 participating centers in Europe were enrolled. Tumor response was evaluated according to the mRECIST criteria. Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were assessed by using Kaplan–Meier analysis and Common Terminology Criteria for Adverse Events, version 5. Liver function deterioration was assessed by monitoring changes in liver blood tests during the follow-up.
Results
Seventy-nine participants (median age, 69 years (IQR, 51–87 years); 67 men (85%)) were enrolled and treated. The median follow-up time was 18 months (IQR 9.5–38.0 months). The estimated median OS and PFS for the entire cohort was 32 months (CI, 95% 21-NaN) and 9 months (CI, 95% 7-NaN), respectively. Eleven (13.9%) participants experienced at least one grade 3 or 4 AE. The most frequent grade 3–4 AE was elevated bilirubin (2.2%, 5 of 79). Deterioration of bilirubin, AST, ALT, and albumin were observed in 24.1%, 23.7%, 19%, and 24% of participants, respectively.
Conclusion
DSM-TACE achieves promising survival in patients with unresectable or recurrent HCC. This technique shows a favorable safety profile both in terms of treatment-related AEs and liver function deterioration. Key Points Question Although degradable starch microspheres transarterial chemoembolization is widely used in clinical practice across Europe, prospective data on its application in hepatocellular carcinoma patients remains limited.
Findings
Degradable starch microspheres transarterial chemoembolization results in promising survival rates, good tumor response rates, and low rates of treatment-related adverse events. Clinical relevance In patients with unresectable hepatocellular carcinoma, degradable starch microspheres transarterial chemoembolization represents a safe and effective alternative to more well-established chemoembolization techniques like conventional transarterial chemoembolization and drug-eluting beads transarterial chemoembolization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Charité University Medicine Berlin Berlin, Charitéplatz 1, 10117, Berlin, Germany. federico.collettini@charite.de.
- Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Straße 2, 10178, Berlin, Germany. federico.collettini@charite.de.
- Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University, Jihlavská 340/20, 625 00, Brno, Czech Republic.
- Department of Radiology, Klinikum Karlsruhe, Moltkestraße 90, 76133, Karlsruhe, Germany.
- Department of Diagnostic and Interventional Radiology, Göttlicher Heiland Krankenhaus, Dornbacher Straße 20-30, 1170, Wien, Austria.
- Department of Radiology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Förderung
- Magle PharmaCept GmbH
Zitieren
APA
Collettini, F., Andrašina, T., Reimer, P., Schima, W., Stroszczynski, C., Lamprecht, Y., Auer, T. A., Rohan, T., Wildgruber, M., Gebauer, B., & Masthoff, M. (2024). Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the Prospective Multicenter Observational HepaStar Trial. European Radiology. https://doi.org/10.1007/s00330-024-11272-8
Vancouver
Collettini F, Andrašina T, Reimer P, Schima W, Stroszczynski C, Lamprecht Y, et al. Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the Prospective Multicenter Observational HepaStar Trial. European Radiology. 2024. doi:10.1007/s00330-024-11272-8
BibTeX
@article{Collettini2024,
author = {Collettini, Federico and Andrašina, Tomáš and Reimer, Peter and Schima, Wolfgang and Stroszczynski, Christian and Lamprecht, Yasmina and Auer, Timo Alexander and Rohan, Tomáš and Wildgruber, Moritz and Gebauer, Bernhard and Masthoff, Max},
title = {Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the Prospective Multicenter Observational HepaStar Trial},
journal = {European Radiology},
year = {2024},
doi = {10.1007/s00330-024-11272-8}
}
EUVIMED